Prostamax
- Category
- Bioregulators
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic tetrapeptide marketed for prostate health, promoted to calm chronic inflammation and support tissue repair as the prostate ages. The case is speculative, resting on mechanistic and animal-model reasoning rather than controlled human trials, with no established human safety profile. A theoretical concern about promoting growth in existing prostate malignancy is unresolved. Products sold online are unregulated, and it is not an approved drug in the US.
Read Full recordStudied uses & evidence
Studied uses(6)
Reduction of chronic prostate inflammation
SpeculativeA rat prostatitis study reports reduced inflammation; human benefit remains unestablished.
Prevention of sclerotic and atrophic processes in prostate tissue
SpeculativeA rat prostatitis study measured sclerosis and atrophy; human prevention remains unestablished.
Epigenetic reactivation of age-silenced genes via chromatin decondensation
LowHuman lymphocyte study found chromatin decondensation signals, but unreplicated and not clinical.
Evidence limits
- Evidence Level
- Preclinical
The peer-reviewed evidence described here is mainly preclinical and ex vivo. Patent RU2177802C1 additionally reports human KEDP treatment series and animal toxicology; these disclosures are not independently validated clinical trials. The cited rat and cell studies do not establish human efficacy or safety. No controlled peer-reviewed human trial was identified. The most substantive evidence comes from the Borovskaya et al. 2013 study in 60 rats, which demonstrated anti-inflammatory, anti-fibrotic, and anti-atrophic effects superior to established comparator agents. Ex vivo studies in human lymphocytes from elderly subjects (Khavinson et al. 2004, Dzhokhadze et al. 2012) show measurable epigenetic effects on chromatin structure. The organotypic tissue culture study (Zakutskii et al. 2006) confirms tissue-specific activity on prostate explants. The major limitations are origin in a single research group, small sample sizes, no peer-reviewed pharmacokinetic or toxicology data, and no independent replication by non-affiliated laboratories.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Very limited human evidence — safety and efficacy remain unestablished
HighTheoretical risk of tumor promotion in active prostate malignancy
TheoreticalUnregulated product quality (research-grade sources)
HighLimited safety data and lack of independent validation
HighAllergic reaction or peptide hypersensitivity
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.